The ALMS1 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the ALMS1 gene. This loss-of-function model enables researchers to investigate ALMS1-dependent cellular processes without the confounding effects of residual protein expression. The polyclonal format ensures a diverse genetic background while maintaining consistent knockout across the cell population, offering a robust tool for functional genomics studies.
The A-549 host cell line was originally isolated from a 58-year-old male patient with lung adenocarcinoma and is widely employed as an in vitro model for lung adenocarcinoma and respiratory epithelium biology. These cells exhibit epithelial morphology and retain key signaling pathways relevant to lung cancer progression, including growth factor receptor cascades and adhesion dynamics. Their well-characterized nature makes them a reliable platform for studying the intersection of ciliary biology and oncogenic signaling.
ALMS1 encodes a centrosomal and ciliary protein critical for maintaining ciliary structure and function. It interacts with core ciliary components such as PCM1 and CEP164, along with cytoskeletal regulators ??-actinin and myosin II, to orchestrate intracellular trafficking and cell cycle progression. Downstream, ALMS1 modulates the activity of AKT, GSK3??, and PKC, placing it at the nexus of insulin/AKT signaling and ciliary-dependent pathways. Disruption of ALMS1 is known to impair hedgehog and Wnt signaling, processes that rely on proper ciliary architecture, thereby influencing cellular proliferation, differentiation, and metabolic responses.
In the context of A-549 lung adenocarcinoma cells, ALMS1 knockout creates a relevant system for dissecting the role of primary cilia in cancer cell biology. Loss of ciliary function can alter tumor cell behavior, including migration, invasion, and drug sensitivity, linking ciliopathy mechanisms to malignancy. This model recapitulates molecular features observed in Alstr?m syndrome, a ciliopathy caused by ALMS1 mutations, and facilitates the study of extrapulmonary manifestations such as insulin resistance and cardiomyopathy, bridging genetic disease and cancer research.
Typical applications of this knockout product include ciliopathy research, Alstr?m syndrome disease modeling, mechanistic studies of insulin signaling, and high-content screens for ciliogenesis modulators. Experimental workflows often integrate western blotting for ALMS1 and downstream effectors (e.g., phospho-AKT, GSK3??), immunofluorescence microscopy for cilia markers (acetylated tubulin, ARL13B), and functional assays such as proliferation, migration/invasion, and insulin sensitivity tests. Drug screening using this polyclonal knockout population can identify compounds that restore ciliary function or bypass signaling defects. For further inquiries, please contact Ascent Research.
